[8-K] Lipocine Inc. Reports Material Event
Lipocine Inc. filed an 8-K reporting a material event: the company submitted a presentation as Exhibit 99.1 for the H.C. Wainwright 27th Annual Global Investor Conference and included the interactive cover page Exhibit 104 in Inline XBRL format. The filing is signed by Mahesh V. Patel, President and Chief Executive Officer, and is dated
Lipocine Inc. ha depositato un 8-K riportando un evento sostanziale: l'azienda ha presentato una presentazione come Exhibit 99.1 per la 27th Annual Global Investor Conference di H.C. Wainwright e ha incluso la pagina di copertina interattiva Exhibit 104 in formato Inline XBRL. Il deposito è firmato da Mahesh V. Patel, Presidente e Amministratore Delegato, ed è datato
Lipocine Inc. presentó un 8-K informando un evento material: la empresa presentó una presentación como Exhibit 99.1 para la 27th Annual Global Investor Conference de H.C. Wainwright e incluyó la portada interactiva Exhibit 104 en formato Inline XBRL. El registro está firmado por Mahesh V. Patel, Presidente y Director Ejecutivo, y está fechado
Lipocine Inc.가 중대한 이벤트를 보고하는 8-K를 제출했습니다: 회사는 Exhibit 99.1로 프리젠테이션을 제출했으며 H.C. Wainwright 27th Annual Global Investor Conference를 위해 작성되었고 대화형 표지 페이지 Exhibit 104를 Inline XBRL 형식으로 포함했습니다. 제출서는 Mahesh V. Patel 회장 겸 최고경영자에 의해 서명되었고 날짜는
Lipocine Inc. a déposé un 8-K signalant un événement important : la société a soumis une présentation en tant que Exhibit 99.1 pour la 27th Annual Global Investor Conference de H.C. Wainwright et a inclus la page de couverture interactive Exhibit 104 au format Inline XBRL. Le dépôt est signé par Mahesh V. Patel, Président et Directeur général, et daté du
Lipocine Inc. hat eine 8-K eingereicht, in der ein wesentlicher Ereignisbericht enthalten ist: Das Unternehmen reichte eine Präsentation als Exhibit 99.1 für die H.C. Wainwright 27th Annual Global Investor Conference ein und schloss die interaktive Titelseite Exhibit 104 im Inline XBRL-Format ein. Die Einreichung wurde von Mahesh V. Patel, Präsident und Chief Executive Officer, unterzeichnet und trägt das Datum
Lipocine Inc. قد قدمت 8-K يورد حدثاً مادياً: قدمت الشركة عرضاً كـ Exhibit 99.1 لـ H.C. Wainwright 27th Annual Global Investor Conference وشملت صفحة الغلاف التفاعلية Exhibit 104 بصيغة Inline XBRL. تم توقيع الملف من قبل Mahesh V. Patel، رئيس مجلس الإدارة والرئيس التنفيذي، ومؤرّخ بتاريخ
Lipocine Inc. 已提交一份 8-K，报道一项重大事件：公司提交了一份作为 Exhibit 99.1 的演示文稿，用于 H.C. Wainwright 第27届年度全球投资者大会，并将互动封面页 Exhibit 104 以 Inline XBRL 格式包含其中。该备案由 Mahesh V. Patel，总裁兼首席执行官签署，日期为
- Exhibit 99.1 presentation furnished for the H.C. Wainwright 27th Annual Global Investor Conference on
September 5, 2025 - Exhibit 104 Inline XBRL cover page included, improving machine-readable disclosure
- No financial results or earnings data were included in the filing
- No material transactions or new agreements were disclosed in this 8-K
Insights
Company disclosed investor presentation materials at a major conference on
The filing registers that a presentation (Exhibit 99.1) for the H.C. Wainwright 27th Annual Global Investor Conference was furnished and that the Inline XBRL cover page (Exhibit 104) was included. This formalizes public dissemination of slides or remarks to investors and satisfies SEC exhibit furnishing requirements.
Because no financial results, guidance, or material agreements were attached, the immediate investor impact is limited to increased disclosure access; monitor any subsequent filings or slide content for new program, clinical, or timeline details over the following weeks.
8-K confirms compliance steps for written communications and exhibit submission.
The submission includes the specified exhibits and a CEO signature, indicating procedural compliance with reporting obligations for investor communications. The form notes checkboxes for solicitation and pre-commencement communications but none are marked, clarifying the nature of the disclosure.
Investors should note that this filing documents disclosure mechanics rather than operational changes; any material developments referenced in the presentation would need their own filings to be separately material and actionable.
Lipocine Inc. ha depositato un 8-K riportando un evento sostanziale: l'azienda ha presentato una presentazione come Exhibit 99.1 per la 27th Annual Global Investor Conference di H.C. Wainwright e ha incluso la pagina di copertina interattiva Exhibit 104 in formato Inline XBRL. Il deposito è firmato da Mahesh V. Patel, Presidente e Amministratore Delegato, ed è datato
Lipocine Inc. presentó un 8-K informando un evento material: la empresa presentó una presentación como Exhibit 99.1 para la 27th Annual Global Investor Conference de H.C. Wainwright e incluyó la portada interactiva Exhibit 104 en formato Inline XBRL. El registro está firmado por Mahesh V. Patel, Presidente y Director Ejecutivo, y está fechado
Lipocine Inc.가 중대한 이벤트를 보고하는 8-K를 제출했습니다: 회사는 Exhibit 99.1로 프리젠테이션을 제출했으며 H.C. Wainwright 27th Annual Global Investor Conference를 위해 작성되었고 대화형 표지 페이지 Exhibit 104를 Inline XBRL 형식으로 포함했습니다. 제출서는 Mahesh V. Patel 회장 겸 최고경영자에 의해 서명되었고 날짜는
Lipocine Inc. a déposé un 8-K signalant un événement important : la société a soumis une présentation en tant que Exhibit 99.1 pour la 27th Annual Global Investor Conference de H.C. Wainwright et a inclus la page de couverture interactive Exhibit 104 au format Inline XBRL. Le dépôt est signé par Mahesh V. Patel, Président et Directeur général, et daté du
Lipocine Inc. hat eine 8-K eingereicht, in der ein wesentlicher Ereignisbericht enthalten ist: Das Unternehmen reichte eine Präsentation als Exhibit 99.1 für die H.C. Wainwright 27th Annual Global Investor Conference ein und schloss die interaktive Titelseite Exhibit 104 im Inline XBRL-Format ein. Die Einreichung wurde von Mahesh V. Patel, Präsident und Chief Executive Officer, unterzeichnet und trägt das Datum
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events |
The Company is presenting and meeting with investors at the H.C. Wainwright 27th Annual Global Investor Conference September 8-10, 2025, in New York City, New York. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibits are filed with this report:
| Exhibit No. | Description | |
| 99.1 | Presentation for the H.C. Wainwright 27th Annual Global Investor Conference | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIPOCINE INC. | ||||
| Date: | September 5, 2025 | By: | /s/ Mahesh V. Patel | |
| Mahesh V. Patel | ||||
| President and Chief Executive Officer | ||||
FAQ
What did Lipocine (LPCN) disclose in the 8-K filed on September 5, 2025 ?
Does the 8-K include earnings or financial tables for LPCN?
Who signed the Lipocine 8-K filing?
Was solicitation or pre-commencement communication indicated in the filing?
Where can investors find the presentation referenced in the 8-K?
